ObjectiveTo evaluate the potential role of Streptococcus salivarius K12 (SSK12) in controlling febrile flares in patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome. Further aims were to assess the impact of SSK12 on (i) flare duration, (ii) variation in the degree of the highest body temperature during flares, (iii) steroid-sparing effect, and (iv) change of PFAPA accompanying symptoms before and after SSK12 introduction. Patients and methodsThe medical charts from 85 pediatric patients with PFAPA syndrome (49 males and 36 females) enrolled in the AIDA registry and treated with SSK12 for a median period of 6.00 +/- 7.00 months in the period between September 2017 and May 2022 were examined. Children recruited had a median time of disease duration of 19.00 +/- 28.00 months. ResultsThe number of febrile flares significantly decreased comparing the 12 months before [median (IQR), 13.00 (6.00)] and after SSK12 initiation [median (IQR), 5.50 (8.00), p < 0.001]. The duration of fever was significantly reduced from 4.00 (2.00) days to 2.00 (2.00) days [p < 0.001]. Similarly, the highest temperature in degrees C was found significantly lower in the last follow-up assessment [median (IQR), 39.00 (1.00)] compared to the period prior to SSK12 start [median (IQR), 40.00 (1.00), p < 0.001]. Steroid load (mg/year) of betamethasone (or any equivalent steroid) significantly decreased between 12 months before treatment with SSK12 [median (IQR), 5.00 (8.00) mg/year] and the last follow-up visit [median (IQR), 2.00 (4.00) mg/year, p < 0.001]. The number of patients experiencing symptoms including pharyngitis/tonsillitis (p < 0.001), oral aphthae (p < 0.001) and cervical lymphadenopathy (p < 0.001) significantly decreased following SSK12. ConclusionSSK12 prophylaxis given for at least 6.00 months was found to reduce febrile flares of PFAPA syndrome: in particular, it halved the total number per year of fever flares, shortened the duration of the single febrile episode, lowered body temperature by 1 degrees C in the febrile flare, provided a steroid-sparing effect, and significantly reduced the accompanying symptoms related to the syndrome.

Preliminary data revealing efficacy of Streptococcus salivarius K12 (SSK12) in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome: A multicenter study from the AIDA Network PFAPA syndrome registry / La Torre, Francesco; Sota, Jurgen; Insalaco, Antonella; Conti, Giovanni; Del Giudice, Emanuela; Lubrano, Riccardo; Breda, Luciana; Maggio, Maria Cristina; Civino, Adele; Mastrorilli, Violetta; Loconte, Roberta; Natale, Marco Francesco; Celani, Camilla; Romeo, Mery; Patroniti, Serena; Gentile, Cristina; Vitale, Antonio; Caggiano, Valeria; Gaggiano, Carla; Diomeda, Federico; Cattalini, Marco; Lopalco, Giuseppe; Emmi, Giacomo; Parronchi, Paola; Gentileschi, Stefano; Cardinale, Fabio; Aragona, Emma; Shahram, Farhad; Marino, Achille; Barone, Patrizia; Moscheo, Carla; Ozkiziltas, Burcugul; Carubbi, Francesco; Alahmed, Ohoud; Iezzi, Ludovica; Ogunjimi, Benson; Mauro, Angela; Tarsia, Maria; Mahmoud, Ayman Abdel-Monem Ahmed; Giardini, Henrique Ayres Mayrink; Sfikakis, Petros P; Laskari, Katerina; Więsik-Szewczyk, Ewa; Hernández-Rodríguez, José; Frediani, Bruno; Gómez-Caverzaschi, Verónica; Tufan, Abdurrahman; Almaghlouth, Ibrahim A; Balistreri, Alberto; Ragab, Gaafar; Fabiani, Claudia; Cantarini, Luca; Rigante, Donato. - In: FRONTIERS IN MEDICINE. - ISSN 2296-858X. - STAMPA. - 10:(2023), pp. 1105605-1105612. [10.3389/fmed.2023.1105605]

Preliminary data revealing efficacy of Streptococcus salivarius K12 (SSK12) in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome: A multicenter study from the AIDA Network PFAPA syndrome registry

La Torre, Francesco;Conti, Giovanni;Lubrano, Riccardo;Maggio, Maria Cristina;Vitale, Antonio;Emmi, Giacomo;Parronchi, Paola;Marino, Achille;Mauro, Angela;
2023

Abstract

ObjectiveTo evaluate the potential role of Streptococcus salivarius K12 (SSK12) in controlling febrile flares in patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome. Further aims were to assess the impact of SSK12 on (i) flare duration, (ii) variation in the degree of the highest body temperature during flares, (iii) steroid-sparing effect, and (iv) change of PFAPA accompanying symptoms before and after SSK12 introduction. Patients and methodsThe medical charts from 85 pediatric patients with PFAPA syndrome (49 males and 36 females) enrolled in the AIDA registry and treated with SSK12 for a median period of 6.00 +/- 7.00 months in the period between September 2017 and May 2022 were examined. Children recruited had a median time of disease duration of 19.00 +/- 28.00 months. ResultsThe number of febrile flares significantly decreased comparing the 12 months before [median (IQR), 13.00 (6.00)] and after SSK12 initiation [median (IQR), 5.50 (8.00), p < 0.001]. The duration of fever was significantly reduced from 4.00 (2.00) days to 2.00 (2.00) days [p < 0.001]. Similarly, the highest temperature in degrees C was found significantly lower in the last follow-up assessment [median (IQR), 39.00 (1.00)] compared to the period prior to SSK12 start [median (IQR), 40.00 (1.00), p < 0.001]. Steroid load (mg/year) of betamethasone (or any equivalent steroid) significantly decreased between 12 months before treatment with SSK12 [median (IQR), 5.00 (8.00) mg/year] and the last follow-up visit [median (IQR), 2.00 (4.00) mg/year, p < 0.001]. The number of patients experiencing symptoms including pharyngitis/tonsillitis (p < 0.001), oral aphthae (p < 0.001) and cervical lymphadenopathy (p < 0.001) significantly decreased following SSK12. ConclusionSSK12 prophylaxis given for at least 6.00 months was found to reduce febrile flares of PFAPA syndrome: in particular, it halved the total number per year of fever flares, shortened the duration of the single febrile episode, lowered body temperature by 1 degrees C in the febrile flare, provided a steroid-sparing effect, and significantly reduced the accompanying symptoms related to the syndrome.
2023
10
1105605
1105612
La Torre, Francesco; Sota, Jurgen; Insalaco, Antonella; Conti, Giovanni; Del Giudice, Emanuela; Lubrano, Riccardo; Breda, Luciana; Maggio, Maria Cristina; Civino, Adele; Mastrorilli, Violetta; Loconte, Roberta; Natale, Marco Francesco; Celani, Camilla; Romeo, Mery; Patroniti, Serena; Gentile, Cristina; Vitale, Antonio; Caggiano, Valeria; Gaggiano, Carla; Diomeda, Federico; Cattalini, Marco; Lopalco, Giuseppe; Emmi, Giacomo; Parronchi, Paola; Gentileschi, Stefano; Cardinale, Fabio; Aragona, Emma; Shahram, Farhad; Marino, Achille; Barone, Patrizia; Moscheo, Carla; Ozkiziltas, Burcugul; Carubbi, Francesco; Alahmed, Ohoud; Iezzi, Ludovica; Ogunjimi, Benson; Mauro, Angela; Tarsia, Maria; Mahmoud, Ayman Abdel-Monem Ahmed; Giardini, Henrique Ayres Mayrink; Sfikakis, Petros P; Laskari, Katerina; Więsik-Szewczyk, Ewa; Hernández-Rodríguez, José; Frediani, Bruno; Gómez-Caverzaschi, Verónica; Tufan, Abdurrahman; Almaghlouth, Ibrahim A; Balistreri, Alberto; Ragab, Gaafar; Fabiani, Claudia; Cantarini, Luca; Rigante, Donato
File in questo prodotto:
File Dimensione Formato  
preliminary.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 767.92 kB
Formato Adobe PDF
767.92 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1305524
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact